Core Viewpoint - InMed Pharmaceuticals has selected an intravitreal formulation for its drug candidate INM-089, aimed at treating dry age-related macular degeneration (AMD), highlighting its potential as an effective therapeutic approach for this condition [1][2]. Company Developments - InMed's proprietary intravitreal (IVT) formulation of INM-089 has shown successful delivery in preclinical studies, achieving doses up to 10 times the calculated safety margin relative to the therapeutic dose level [2][6]. - The company has completed a series of dose-ranging in vivo studies to guide the selection of appropriate doses for pivotal preclinical toxicology studies [3]. Industry Context - AMD is a prevalent progressive eye disease affecting an estimated 196 million people globally, with dry AMD accounting for approximately 80% of cases [5]. - There is a significant unmet medical need for effective treatments for dry AMD, particularly as it impacts about 12.6% of Americans aged 40 and older [5].
InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration